Insilico Medicine expanded its existing AI-powered drug discovery collaboration with Eli Lilly in a deal worth up to $2.75 billion. The agreement validates Insilico's AI platform, should drive milestone payments and near-term upside for Insilico, and is likely to boost valuations among biotech/AI crossover peers while having limited broader market impact.
Insilico Medicine expanded its existing AI-powered drug discovery collaboration with Eli Lilly in a deal worth up to $2.75 billion. The agreement validates Insilico's AI platform, should drive milestone payments and near-term upside for Insilico, and is likely to boost valuations among biotech/AI crossover peers while having limited broader market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
